Navigation Links
New technology to improve early detection and prognosis of cancer
Date:3/24/2011

Grand Rapids, Mich. (March 24, 2011) Gentel Biosciences, a leader in proteomics tools, and Van Andel Research Institute (VARI), a biomedical research institute, jointly announce today the granting of U.S. Patent 7,838,634 for a new method to profile changes in the glycosylation of proteins captured on the surface of an antibody array slide. Gentel first obtained an exclusive right to commercialize the technology in 2006.

According to Brian H. Haab, Ph.D., head of VARI's Laboratory of Cancer Immunodiagnostics and inventor of the technology, "A number of new biomarkers using glycosylated variants of proteins have recently received or are proceeding toward FDA clearance. The ability to efficiently screen glycosylated variants of many proteins for use as biomarkers offers an unprecedented opportunity for discoveries of new glycan-based biomarkers."

Glycosylation is the addition of linear or branched sugar molecules to proteins. Many studies have shown that glycosylated variants of proteins can make better markers for early detection and for prognosis in cancers like hepatocellular carcinoma when compared to measuring the protein alone.

"There is a lack of tools to screen proteins for changes in glycosylation that might be associated with disease. Dr. Haab's approach is a better method to identify new diagnostic biomarkers based on glycosylated variants of proteins," added Bryce P. Nelson, Ph.D., Vice President of Technology and Business Development at Gentel Biosciences.

A patent for the technology is also pending in the European Union.

The new glycan detection technology will soon be combined with the more than fifty SilverQuant Antibody Array kits available from Gentel. These antibody array kits target nearly 500 proteins and provide a complete proteomics workflow from screening to quantification. SilverQuant kits are configured for use with the Gentel Proteomics Multi-System and Gentel's AthenaQuant analysis software for an easy-to-use and cost-effective alternative with better sensitivity than fluorescence-based detection. SilverQuant chromogenic technology allows for the detection of any biotinylated molecule, generating array spots that are visible to the naked eye that can be detected with the Gentel Proteomics Multi-System. Simple protocols empower both experts and novices to obtain meaningful protein multiplexing data in a single day.


'/>"/>

Contact: Joe Gavan
joe.gavan@vai.org
616-234-5390
Van Andel Research Institute
Source:Eurekalert

Related biology news :

1. U of M researchers close in on technology for making renewable petroleum
2. University of Houston wins $1 million EPA grant to test diesel technology on buses
3. AMIA on meaningful use: Invest in people and technology
4. Cleveland Clinic researchers honored for contributions to science and technology
5. DHS Science and Technology Directorates science conference: Catastrophes and Complex Systems
6. NextCAT secures license agreement for advanced biofuel technology from Wayne State
7. New technology pinpoints genetic differences between cancer and non-cancer patients
8. Groundbreaking technology will revolutionize blood pressure measurement
9. Stanford researchers develop new technology for cheaper, more efficient solar cells
10. Immunologist J. John Cohen receives the 2010 AAAS Public Understanding of Science and Technology Award
11. New MegaMatcher 4.0 from Neurotechnology Integrates Fingerprint, Iris, Facial and Palmprint Biometrics In One High-Performance SDK
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2016)... 2016   The Weather Company , an IBM Business ... industry-first capability in which consumers will be able to interact ... questions via voice or text and receive relevant information about ... Marketers have long sought an advertising solution that can ... personal, relevant and valuable; and can scale across millions of ...
(Date:5/24/2016)... 24, 2016 Ampronix facilitates superior patient care by providing unparalleled technology to ... display is the latest premium product recently added to the range of products distributed ... ... ... Imaging- LCD Medical Display- Ampronix News ...
(Date:5/12/2016)... DALLAS , May 12, 2016 ... has just published the overview results from the Q1 ... of the recent wave was consumers, receptivity to a ... wearables data with a health insurance company. ... choose to share," says Michael LaColla , CEO ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... DIEGO , June 24, 2016 ... more sensitively detects cancers susceptible to PARP inhibitors ... circulating tumor cells (CTCs). The new test has ... HRD-targeted therapeutics in multiple cancer types. ... targeting DNA damage response pathways, including PARP, ATM, ...
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, a leader in clinical ... Patient Recruitment and Retention Tips.” Partnering with experienced clinical research professionals, Mosio revisits ... tips, tools, and strategies for clinical researchers. , “The landscape of how patients ...
(Date:6/23/2016)... TORONTO , June 23, 2016 /PRNewswire/ - ... Ontario biotechnology company, Propellon ... the development and commercialization of a portfolio of ... cancers. Epigenetic targets such as WDR5 represent an ... contribute significantly in precision medicine for cancer patients. ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... (Yeast and Mold) microbial test has received AOAC Research Institute approval 061601. , ... tests introduced last year,” stated Bob Salter, Vice President of Regulatory and Industrial ...
Breaking Biology Technology: